Due to observing dramatically different Trastuzumab anti-tumor responses within two xenograft models with the same HER-2 level (2+), but differing PIK3CA mutation status, we sought to determine the AKT pathway activation states within tumor lysates from these models. Here, ERBB2 is linked to neoplasm.